Research progress on pharmacological effects and bioavailability of berberine.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analysis
PubMed 38888754 · doi:10.1007/s00210-024-03199-0
What was done
This narrative review summarizes the reported pharmacological activities of berberine, examines the biological and chemical causes of its poor bioavailability, and evaluates strategies to enhance absorption, including absorption enhancers, P-glycoprotein inhibitors, chemical modifications, salts, cocrystals, and novel formulation technologies.
What was found
The review notes that berberine has diverse reported actions (including neuroprotective, cardiovascular, anti-inflammatory, antidiabetic, antihyperlipidemic, antitumor, antibacterial, and antidiarrheal effects), but has an oral bioavailability of less than 1% (< 1%). The low bioavailability is attributed to poor solubility, low permeability, P-glycoprotein efflux, and hepatic-intestinal metabolism. No other specific quantitative figures or comparative data are reported in the abstract.
Why it matters
Understanding the specific pharmacokinetic barriers to berberine absorption is essential for designing delivery systems that could translate its preclinical bioactivities into clinical efficacy.
Limits
This is a narrative review without systematic search methods or quantitative meta-analysis. The abstract provides no primary experimental data, specific effect sizes, or clinical trial outcomes in humans.
Cited by
- supports Less than 1% of standard oral berberine and curcumin is absorbed across the intestinal barrier.